

A β 40 Reduces P-Glycoprotein at the Blood–Brain Barrier through the Ubiquitin–Proteasome Pathway

Anika M.S. Hartz,^{1,2,3}  Yu Zhong,¹ Andrea Wolf,³ Harry LeVine, III,¹ David S. Miller,⁴ and Björn Bauer^{3,5}

¹Sanders-Brown Center on Aging and ²Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, Kentucky 40536,

³Department of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, University of Minnesota, Duluth, Minnesota 55812, ⁴Laboratory of Signal Transduction, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709, and

⁵Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536

Failure to clear amyloid- β (A β) from the brain is in part responsible for A β brain accumulation in Alzheimer's disease (AD). A critical protein for clearing A β across the blood–brain barrier is the efflux transporter P-glycoprotein (P-gp) in the luminal plasma membrane of the brain capillary endothelium. P-gp is reduced at the blood–brain barrier in AD, which has been shown to be associated with A β brain accumulation. However, the mechanism responsible for P-gp reduction in AD is not well understood. Here we focused on identifying critical mechanistic steps involved in reducing P-gp in AD. We exposed isolated rat brain capillaries to 100 nM A β 40, A β 40, aggregated A β 40, and A β 42. We observed that only A β 40 triggered reduction of P-gp protein expression and transport activity levels; this occurred in a dose- and time-dependent manner. To identify the steps involved in A β -mediated P-gp reduction, we inhibited protein ubiquitination, protein trafficking, and the ubiquitin–proteasome system, and monitored P-gp protein expression, transport activity, and P-gp-ubiquitin levels. Thus, exposing brain capillaries to A β 40 triggers ubiquitination, internalization, and proteasomal degradation of P-gp. These findings may provide potential therapeutic targets within the blood–brain barrier to limit P-gp degradation in AD and improve A β brain clearance.

Key words: Alzheimer's disease; blood–brain barrier; P-glycoprotein; transporter; ubiquitin–proteasome system

Significance Statement

The mechanism reducing blood–brain barrier P-glycoprotein (P-gp) in Alzheimer's disease is poorly understood. In the present study, we focused on defining this mechanism. We demonstrate that A β 40 drives P-gp ubiquitination, internalization, and proteasome-dependent degradation, reducing P-gp protein expression and transport activity in isolated brain capillaries. These findings may provide potential therapeutic avenues within the blood–brain barrier to limit P-gp degradation in Alzheimer's disease and improve A β brain clearance.

Introduction

The etiology of excess amyloid- β (A β) brain accumulation in Alzheimer's disease (AD) is poorly understood. One contributing

factor to A β brain accumulation is reduced A β clearance from the brain (Zlokovic and Frangione, 2003; Zlokovic, 2005). A neurovascular component in A β clearance has been implicated, suggesting that the blood–brain barrier is key in this process (Zlokovic and Frangione, 2003; Zlokovic, 2005). Studies show that P-glycoprotein (P-gp), an efflux transporter in the luminal plasma membrane of brain capillaries, is critical for clearing A β from brain into blood (Lam et al., 2001; Cirrito et al., 2005; Kuhnke et al., 2007; Hartz et al., 2010). We and others showed that P-gp protein expression and transport activity levels are reduced in brain capillaries from AD mouse models, suggesting a link between high A β levels and reduced levels of brain capillary P-gp (Hartz et al., 2010; Mehta et al., 2013).

Received Jan. 27, 2015; revised Dec. 9, 2015; accepted Dec. 15, 2015.

Author contributions: A.M.S.H. and D.S.M. designed research; A.M.S.H., Y.Z., A.W., H.L., and B.B. performed research; A.M.S.H., A.W., H.L., D.S.M., and B.B. analyzed data; A.M.S.H., Y.Z., D.S.M., and B.B. wrote the paper.

This work was supported by National Institute on Aging Grant 1R01AG039621 to A.M.S.H., 3M Science and Technology Doctoral Fellowship to A.W., 3M Grant P01-AG005119-20 to H.L., and the Division of Intramural Research at National Institute of Environmental Health Sciences/National Institutes of Health to D.S.M. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Aging or the National Institutes of Health. We thank Stephanie Edelmann, Ralf Remppe, Yu Zhong, and Tal Ashkenazi-Frolinger for proofreading the manuscript and editorial assistance; Britt Johnson, Kevin Viken, and Emma Soldner for technical assistance; and Lynne Bemis and Evan Odean for the NanoSight analysis.

The authors declare no competing financial interests.

Correspondence should be addressed to Dr. Anika M.S. Hartz, University of Kentucky, 329 Sanders-Brown Center on Aging, Department of Pharmacology and Nutritional Sciences, 800 South Limestone, Lexington, KY 40536-0230. E-mail: anika.hartz@uky.edu.

DOI:10.1523/JNEUROSCI.0350-15.2016
Copyright © 2016 the authors 0270-6474/16/361930-12\$15.00/0

Indeed, an inverse relationship between A β and P-gp protein levels has been observed in postmortem human brain samples (Wijesuriya et al., 2010; Jeynes and Provias, 2011), and capillary P-gp levels are significantly reduced and even undetectable in brain regions with high A β levels (Vogelgesang et al., 2002, 2004). Carrano et al. (2014) demonstrated that P-gp protein levels are reduced in human brain microvessels affected by high microvascular A β load in cerebral amyloid angiopathy. This was not observed in healthy individuals and AD patients without vascular amyloid deposits. Finally, PET studies in patients with mild and advanced AD confirmed that P-gp-mediated transport of [11 C]-verapamil at the blood–brain barrier is lower than that in age-matched healthy individuals (van Assema et al., 2012; Deo et al., 2014). Collectively, these findings demonstrate an association between A β brain levels and blood–brain barrier P-gp. They suggest that P-gp is critical for A β clearance and that reduced P-gp protein expression and transport activity result in excessive A β brain accumulation.

The mechanism reducing blood–brain barrier P-gp in AD is poorly understood. In the present study, we focused on defining this mechanism. We demonstrate that A β 40 drives P-gp ubiquitination-, internalization-, and proteasome-dependent degradation, reducing P-gp protein expression and transport activity in isolated brain capillaries. These findings may provide potential therapeutic avenues within the blood–brain barrier to limit P-gp degradation in AD and improve A β brain clearance.

Materials and Methods

Chemicals. A11 antibody against A β 40 oligomers, C219 antibody against P-gp, and antibodies against RAGE and β -actin were purchased from Abcam. Antibodies against LRP and ubiquitin, and purified IgG control antibody were obtained from Calbiochem-Novabiochem. OC antibody against A β 40 was purchased from EMD Millipore, and antibodies 6E10 and 4G8, which recognize both A β 40 and A β 42, were obtained from Covance. Pierce Protein A/G Plus beaded agarose resin was obtained from Thermo Scientific, and the 20 S Proteasome Assay kit was purchased from Cayman Chemical. PYR-41 and bortezomib were from Selleckchem. [N- ϵ (4-Nitrobenzofurazan-7-yl)-D-Lys8]-cyclosporin A (NBD-CSA) was custom-synthesized by R. Wenger (Basel, Switzerland) (Schramm et al., 1995). PSC833 was a kind gift from Novartis. AggreSure β -Amyloid (1–40) (#AS-72215) was obtained from AnaSpec. Human A β 1–40 (A β 40), A β 1–42 (A β 42), and A β 40–1_{reverse} (A β 40_{reverse}) and all other chemicals were purchased from Sigma-Aldrich.

Animals. All animal experiments were approved by the Institutional Animal Care and Use Committee of the University of Kentucky and University of Minnesota (UK protocol #2014–1233, principal investigator A.M.S.H.; UMN protocol #0710A17842 and #1110A05865, principal investigator A.M.S.H.) and performed in strict accordance with Association for Assessment and Accreditation of Laboratory Animal Care regulations, the Department of Agriculture Animal Welfare Act, and the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Male Sprague Dawley rats (CD IGS rats; 275–300 g; 8–10 weeks) were purchased from Charles River. After shipping, rats were allowed to adapt to the new environment for a minimum of 5 d before they were used for experiments. Rats were kept under controlled environmental conditions (23°C, 35% relative humidity, 12 h dark-light cycle) with free access to tap water and standard rodent chow.

A β ELISA. Total and oligomer-specific A β measurements were performed by ELISA (LeVine, 2004). Capture antibodies were immobilized on ELISA plates (Costar 9018). Total (monomeric + oligomeric) A β 40 was determined by capturing with monoclonal antibody 6E10 (amino acids 3–8) and detecting with biotinylated monoclonal antibody 4G8 (amino acids 17–24). Oligomeric hA β 40 was determined by capturing with nonbiotinylated 4G8 and detecting with biotinylated 4G8 antibody. Capturing and detecting with the 4G8 antibodies to the same epitope recognize only oligomeric A β 40 because the 4G8 epitope in the A β

monomer is sequestered by the capture antibody and is not accessible to the biotinylated 4G8. The bound biotinylated 4G8 is quantified by streptavidin-HRP (Rockland Immunochemicals) and H $_2$ O $_2$ /tetramethylbenzidine peroxidase substrate.

Brain capillary isolation. Rat brain capillaries were isolated as previously described (Hartz et al., 2004, 2008, 2010; Bauer et al., 2006). Briefly, rats were killed by CO $_2$ inhalation and decapitated. Brains were removed, cleaned, dissected, and homogenized in ice-cold PBS (2.7 mM KCl, 1.46 mM KH $_2$ PO $_4$, 136.9 mM NaCl, 8.1 mM Na $_2$ HPO $_4$, supplemented with 5 mM D-glucose and 1 mM sodium pyruvate, pH 7.4). Ficoll PM400 was added to the homogenate to a final concentration of 15%, and the Ficoll-brain homogenate mix was centrifuged at 5800 \times g for 20 min at 4°C. After resuspending the pellet in PBS containing 1% BSA (w/v), the capillary suspension was passed over a 40 ml glass bead column (0.4–0.6 mm; Sartorius StedimBiotech). Capillaries adhering to the glass beads were washed off the beads and collected in 1% BSA. Capillaries were washed with PBS (BSA-free) and used for experiments.

P-gp transport assay. To determine P-gp transport activity, freshly isolated brain capillaries were incubated for 1 h at room temperature with the fluorescent P-gp-specific substrate NBD-CSA (2 μ M in PBS buffer) (Hartz et al., 2004, 2008, 2010). For each treatment, images of 10 capillaries were acquired by confocal microscopy using a Zeiss LSM 710 inverted confocal microscope with a 40 \times 1.2 NA water-immersion objective and using the 488 nm line of an argon laser (Carl Zeiss). Images were analyzed by quantitating NBD-CSA fluorescence in the capillary lumen using ImageJ version 1.45s (Wayne Rasband, National Institutes of Health). Specific, luminal NBD-CSA fluorescence was taken as the difference between total luminal fluorescence and fluorescence in the presence of the P-gp-specific inhibitor PSC833 (5 μ M) (Hartz et al., 2004, 2008, 2010).

Western blotting. Protein expression levels in brain capillaries were analyzed by Western blotting as previously described (Hartz et al., 2004, 2008, 2010). Briefly, brain capillaries were homogenized in CellLytic MT cell lysis buffer (Sigma) containing Complete protease inhibitor (Roche). Homogenized brain capillary samples were centrifuged at 10,000 \times g for 15 min at 4°C to remove nuclei, followed by a centrifugation of the denucleated supernatants at 100,000 \times g for 90 min at 4°C to obtain brain capillary crude membranes. Brain capillary membranes were resuspended in buffer containing protease inhibitor and stored at –80°C until use.

Western blotting was done using the Invitrogen NuPage Bis-Tris electrophoresis and blotting system. After electrophoresis and protein transfer (30 V, 2 h), PVDF membranes (0.45 μ m pore size) were blocked with protein-free T20 blocking buffer (Pierce) and incubated overnight with the primary antibody diluted in blocking buffer as indicated (C219, β -actin, ubiquitin, LRP, RAGE: all at 1 μ g/ml). PVDF blotting membranes were washed and incubated with HRP-conjugated ImmunoPure secondary IgG (1:15,000; Pierce) for 1 h. Proteins were detected using SuperSignal West Pico Chemoluminescent Substrate (Pierce), and protein bands were visualized and imaged using a Bio-Rad Gel Doc 2000 gel documentation system with Quantity One software (Bio-Rad).

Dot blotting. Dot blots were performed using the Whatman Minifold I 96-well system on Whatman Protran BA79 nitrocellulose membranes (pore size 0.1 μ m, GE Healthcare). Blots were blocked, incubated, washed, and imaged as described in Western blotting.

Immunoprecipitation. For immunoprecipitations, identical protein amounts (determined by Bradford assay) of Protein A/G bead-purified capillary lysates were incubated with 5 μ g P-gp antibody overnight at 4°C. The immune complexes were collected with Protein A/G agarose beads (2 h, room temperature), washed four times with RIPA buffer (150 mM NaCl, 1.0% IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0; Sigma-Aldrich) followed by a PBS wash. For ubiquitin immunoprecipitations, a ubiquitin enrichment kit from Pierce/Thermo Scientific was used according to the manufacturer's protocol. Immunoprecipitated proteins were eluted from agarose beads (IP: P-gp) or the ubiquitin affinity resin (IP: ubiquitin) with NuPAGE LDS sample buffer or Wes sample buffer and heated at 70°C for 10 min. IP samples eluted with NuPAGE LDS sample buffer were resolved by SDS-PAGE and analyzed by Western blotting as described above. Sam-

ples eluted with Wes sample buffer (see Fig. 5D; IP Ubiquitin) were analyzed and quantitated with a Simple Western assay using the Wes instrument (ProteinSimple). The Simple Western assay is a capillary electrophoresis technique that automates protein loading, separation, immunoprobings, washing, and detection, and allows absolute protein quantitation (O'Neill et al., 2006; Beccano-Kelly et al., 2014). For the assay, reagents of the Wes Master Kit (ProteinSimple) were used, and all steps of the assay were performed according to the manufacturer's protocol. A Wes Master Kit capillary cartridge and the prepared microplate were placed into the Wes instrument, which processed all assay steps automatically using default settings. Briefly, capillaries were loaded with both stacking and separation matrices followed by sample loading. During capillary electrophoresis, proteins were separated by size and then immobilized to the capillary wall. P-gp and ubiquitin were identified with primary antibodies against P-gp (C219, Thermo Scientific, 1:150) and ubiquitin (ubiquitin antibody, Abcam, 1:20), respectively, followed by immunodetection using Wes Master Kit HRP-conjugated anti-mouse secondary antibody and chemiluminescent substrate. Protein signals were automatically reported by the Compass software (version 2.6.5; ProteinSimple). Using Compass software, electropherograms were generated for each capillary (treatment group) and each protein (P-gp, ubiquitin), and the area under the curve was analyzed for P-gp. The area under the curve represents the signal intensity of the chemiluminescent reaction and is proportional to the amount of target protein in a respective capillary.

20S proteasome activity assay. We used the 20S proteasome assay kit from Cayman Chemical and followed the protocol provided by the manufacturer. Isolated capillaries were lysed in 20S proteasomal lysis buffer. Capillary lysate was incubated with 10 μ l assay buffer and 10 μ l proteasome substrate (SUC-LLVY-AMC) for 1 h at 37°C. Fluorescence intensity (ex 360 nm, em 480 nm) was measured using a microplate reader.

Statistical analysis. Data are mean \pm SEM. ANOVA or a two-tailed unpaired Student's *t* test was used to evaluate differences between controls and treated groups using Microsoft Excel 2010 and GraphPad Prism (version 6.01); differences were considered to be statistically significant when *p* < 0.05.

Results

Identification of A β forms

For the experiments described in the present study, we used 100 nM human A β 40 dissolved in PBS supplemented with 5 mM D-glucose and 1 mM sodium pyruvate (pH 7.4, 25°C \pm 0.5°C). We used several methods to identify the form in which A β 40 was present in this solution. These involved measurements of A β 40 monomer versus oligomer 0, 1, 6, and 24 h after preparation of the A β 40 working solu-




Figure 1. Determination of A β 40 forms. **A**, Western blot showing bands for A β 40 at 4 kDa with 4G8 antibody (recognizes A β 17–24), weak bands at 4 kDa with 6E10 antibody (recognizes A β 1–17), and no bands with A11 antibody (detects amyloid oligomers) and faint bands with OC antibody (detects amyloid fibrils) 0, 1, 6, and 24 h after making the 100 nM A β 40 working solution in PBS. **B**, Dot blots showing low A β 40 levels with 4G8, 6E10, A11, and OC antibodies that are decreasing over the course of 24 h. **C**, Oligomer-specific configuration ELISA shows that the total amount of A β 40 in solution decreases over time.




Figure 2. A β 40 reduces P-gp protein expression and transport function. Representative confocal microscopy images of isolated brain capillaries that were exposed to 100 nM A β 40 for 6 h and then exposed to the fluorescent P-gp substrate NBD-CSA (marker for P-gp transport activity). **A**, Representative image of an isolated brain capillary after 1 h of exposure to 2 μ M NBD-CSA, showing steady-state NBD-CSA fluorescence. **B**, NBD-CSA fluorescence in the capillary lumen is reduced in capillaries that were exposed to A β 40 for 6 h, indicating a decrease in P-gp transport activity. **C**, Specific NBD-CSA fluorescence in the capillary lumen was obtained through analysis of the confocal images and shows decreased luminal fluorescence in capillaries exposed to 100 nM A β 40. **D**, Western blot showing that 100 nM A β 40 reduces P-gp protein expression but has no effect on LRP or RAGE protein expression levels. **E**, Western blot showing that P-gp protein levels in capillaries exposed to 10–100 nM A β 40 for 1 h remain at control levels. In contrast, P-gp transport activity levels decreased. **F**, Western blot showing that P-gp protein and transport activity levels decreased in a concentration-dependent manner after 6 h of A β 40 exposure. β -Actin was used as protein loading control for Western blots. **C, E, F**, Data were obtained through analysis of the confocal images. Specific NBD-CSA fluorescence is the difference between total luminal fluorescence and fluorescence in the presence of the specific P-gp inhibitor PSC833, representing specific P-gp transport activity. Data are mean \pm SEM ($n = 10$ –15 capillaries per treatment group from one brain capillary isolation; pooled tissue from 10 rats). Units are arbitrary fluorescence units (scale, 0–255). *** $p < 0.001$, significantly lower than control.

tion. With Western blotting (LDS-PAGE under reducing conditions), we detected a band at 4 kDa for A β 40 monomer with 4G8 antibody (recognizes A β 17–24) and a weaker signal with 6E10 antibody (recognizes A β 1–17; Fig. 1A). However, by Western blotting, we detected no A β 40 oligomer bands using A11 antibody (detects amyloid oligomers) and faint bands using OC antibody (detects amyloid fibrils). Dot blot analysis using the same antibodies indicated that A β 40 monomer and low levels of A β 40 oligomer were present in the solution, but the amount of A β 40

decreased over 24 h (Fig. 1B). By sandwich ELISA, we found a decreasing amount of total A β 40 over time (Fig. 1C), which is likely due to nonspecific binding of the A β 40 monomer to the test tube. By an oligomer-specific configuration sandwich ELISA, we observed a very low A β 40 oligomer signal. The total amount of all A β 40 species detectable in solution decreased dramatically over time. The lack of oligomeric A β 40 under these conditions is not surprising as synthetic A β 40 oligomerizes weakly *in vitro* (LeVine, 2004). Thus, the 100 nM A β 40 solution used for our experiments

primarily consisted of monomeric A β 40. In an attempt to determine the size distribution of the various A β 40 forms in the solution/dispersion, we performed nanoparticle tracking analysis using a NanoSight LM10 (Malvern Instruments). However, the A β 40 concentration (100 nM) was too low, and the analysis was inconclusive (data not shown). Overall, these results are consistent with other findings showing that A β 40 remains predominantly monomeric in aqueous buffer solutions, such as PBS (Stine et al., 2011).

A β 40 reduces P-gp protein expression and transport activity

We measured P-gp protein expression and transport activity levels in freshly isolated rat brain capillaries that were exposed to 100 nM human A β 40 for 1 or 6 h. After removing A β 40, P-gp transport activity was determined by incubating brain capillaries with the P-gp-specific fluorescent substrate NBD-CSA (2 μ M) and by measuring fluorescence of this dye in the capillary lumens by confocal microscopy and quantitative image analysis as described previously (Hartz et al., 2008, 2010). Figure 2 depicts representative images of a control brain capillary (no A β 40) and a brain capillary exposed to A β 40 for 6 h. Luminal NBD-CSA fluorescence was substantially decreased in capillaries exposed to A β 40 compared with control capillaries (Fig. 2*A,B*). Image analysis revealed a reduction of $69.4 \pm 6.2\%$ (average of 10 independent experiments) in luminal NBD-CSA in brain capillaries exposed to A β 40, indicating that A β 40 reduced P-gp transport activity (Fig. 2*C*). This result is consistent with our previous data in isolated brain capillaries from wild-type and

transgenic hAPP mice, where we observed a comparable reduction of P-gp transport activity levels with A β 40 exposure (Hartz et al., 2010; their Fig. 2*A,B*). In addition to reduced P-gp transport activity, we also found a reduction of $40.3 \pm 6.2\%$ (average of 10 independent experiments) in P-gp protein expression in brain capillary membranes isolated from A β 40-treated brain capillaries (6 h treatment). A β 40 exposure did not affect protein expression levels of LRP1 ($100 \pm 4\%$ compared with control, average of three independent experiments) and RAGE ($95 \pm 5.6\%$ compared with control, average of three independent experiments; Fig. 2*D*). Dose–response experiments showed that both 1 and 6 h exposure of brain capillaries to 10, 50, and 100 nM A β 40 reduced P-gp transport activity in a concentration-dependent manner, whereas only the 6 h exposure of capillaries to A β 40 reduced P-gp protein expression levels (Fig. 2*E,F*). It is unlikely that A β 40 acts as P-gp inhibitor because A β 40-mediated reduction the effect can be abolished by inhibitors of the ubiquitin–proteasome pathway (data not shown). Thus, nanomolar concentrations of human A β 40 trigger reduction of both P-gp expression and transport activity levels in isolated rat brain capillaries, but the time courses of loss of transport activity and loss of transporter protein expression levels differed.




Figure 3. Time course of A β 40-mediated P-gp reduction. **A**, The effect of A β 40 on P-gp transport activity is reversible. Capillaries were loaded for 60 min to steady state with 2 μ M NBD-CSA. When 100 nM A β 40 was added to the buffer (time 0 on graph), P-gp transport activity decreased rapidly; P-gp activity stayed decreased in capillaries exposed to A β 40 for 6 h but recovered completely when A β 40 was removed at time point 45 min. Western blot showing (**B**) no change of P-gp protein expression after 45 min exposure to A β 40 and (**C**) no change of P-gp expression in capillaries that were first exposed to A β 40 for 45 min followed by 5 1/4 h in A β 40-free buffer (total experiment duration of 6 h). **D**, Consistent with Figure 2, Western blot showing reduced P-gp protein expression after 6 h exposure to A β 40. β -Actin was used as a protein loading control for all Western blots. Data are mean \pm SEM ($n = 10$ –15 capillaries per treatment group from one brain capillary isolation; pooled tissue from 10 rats). Units are arbitrary fluorescence units (scale, 0–255). * $p < 0.05$, significantly lower than control. ** $p < 0.01$, significantly lower than control. *** $p < 0.001$, significantly lower than control.

To determine the effect of 100 nM A β 40 on P-gp transport activity over time, we preincubated isolated rat brain capillaries with 2 μ M NBD-CSA for 1 h to a steady state before adding A β 40, and then monitored brain capillaries over 6 h. Figure 3*A* shows that luminal NBD-CSA fluorescence in control capillaries (no A β 40) did not change over the 6 h time course (Hartz et al., 2010). In contrast, addition of A β 40 reduced P-gp transport activity levels within 15 min. After 45 min, P-gp transporter activity was substantially decreased to a level that was comparable with that seen when P-gp was inhibited with PSC833; P-gp transport activity remained at this low level for the entire 6 h of A β 40 exposure. Removing A β 40 from the buffer medium after 45 min restored P-gp transport activity to control levels over the course of 6 h.

P-gp protein expression levels were unchanged after a 45 min A β 40 exposure (Fig. 3*B*) and remained unchanged when A β 40 was removed from the medium after 45 min and incubation in A β 40-free medium continued for an additional 5 1/4 h (Fig. 3*C*). In contrast, brain capillaries that were exposed to A β 40 for a total of 6 h exhibited reduced P-gp protein expression levels (Fig. 3*D*). The A β -mediated reduction of P-gp expression and transport activity levels was not reversible when A β 40 was not removed after 45 min. Thus, A β 40-mediated




Figure 4. Aggregated A β 40, reverse A β 40, and A β 42 have no effect on P-gp. Exposing capillaries to 100 nM A β 40 decreases P-gp protein expression (Western blot) and transport activity (luminal NBD-CSA fluorescence). Aggregated A β 40 (**A**, **B**), A β 40_{reverse} (reverse amino acid sequence of A β 40) (**C**), and A β 42 (**D**) had no effect on P-gp expression or activity. β -Actin was used as protein loading control for Western blots. Data are mean \pm SEM ($n = 10$ capillaries per treatment group from one brain capillary isolation; pooled tissue from 10 rats). Units are arbitrary fluorescence units (scale, 0–255). *** $p < 0.001$, significantly lower than control.

reduction of P-gp transport activity levels occurs within 15 min of initial A β 40 exposure followed by a reduction in P-gp protein expression levels. The initial reduction in P-gp expression and transport activity levels is reversible when A β 40 exposure of brain capillaries is limited to ≤ 45 min but becomes irreversible when A β 40 remains in the medium for > 45 min. This indicates that the transporter is degraded after 45 min of A β 40 exposure, after which P-gp expression and transport activity cannot be restored.

In a series of control experiments, we exposed isolated rat brain capillaries to the aggregated form of A β 40, to a peptide with the reverse sequence of that for A β 40 (A β 40_{reverse}), and to A β 42.

In contrast to monomeric A β 40, 6 h exposure of isolated rat brain capillaries to aggregated A β 40 did not affect P-gp protein expression and transport activity (Fig. 4A, B). LRP and RAGE protein expression levels also remained unchanged by the aggregated form of A β 40. When we exposed isolated rat brain capillaries to A β 40_{reverse} (Fig. 4C) or to human A β 42 (Fig. 4D) for 6 h, P-gp protein expression and transport activity did not change either. These data indicate that, under these experimental conditions (100 nM of respective human A β species for 6 h), reduction in P-gp protein expression and transport activity levels in isolated rat brain capillaries is specific to A β 40, whereas aggregated A β 40, A β 40_{reverse}, or A β 42 had no effect.




Figure 5. A β 40 triggers ubiquitination of P-gp. **A**, Isolated capillaries were exposed to 100 nM A β 40. After 6 h, P-gp was immunoprecipitated and examined for P-gp and ubiquitin by Western blotting. Capillaries exposed to A β 40 showed increased ubiquitination. IgG control: capillary lysate sample plus IgG antibody; negative control: capillary lysate sample but no primary antibody. **B**, Cross-experiment showing immunoprecipitation of ubiquitin followed by Western blot analysis of P-gp and ubiquitin. Increased ubiquitination of P-gp was found in capillaries exposed to A β 40. **C**, The ubiquitin ligase inhibitor PYR-41 (10 μ M) prevented A β 40-mediated reduction of P-gp expression (Western blot, β -actin was used as protein loading control) and transport activity (luminal NBD-CSA fluorescence). **D**, P-gp and ubiquitin were immunoprecipitated and examined for P-gp and ubiquitin by Western blotting and simple Western assay using the Wes instrument. PYR-41 prevented P-gp ubiquitination in capillaries exposed to 100 nM A β 40. Data are mean \pm SEM ($n = 10$ capillaries per treatment group from one brain capillary isolation; pooled tissue from 10 rats). Units are arbitrary fluorescence units (scale, 0–255). *** $p < 0.001$, significantly lower than control.

A β 40 activates the ubiquitin–proteasome pathway

To determine whether exposure to human A β 40 triggers the reduction in P-gp protein expression and transport activity levels by activating the ubiquitin–proteasome pathway, we exposed isolated rat brain capillaries to 100 nM A β 40 for 6 h, immunoprecipitated P-gp or ubiquitin from capillary lysates, and separated protein samples by SDS-PAGE and Western blotting. The Western blot in Figure 5A (P-gp immunoprecipitation) shows increased ubiquitin levels in brain capillaries treated with A β 40. In the cross-experiment (Fig. 5B) where we immunoprecipitated ubiquitin, we observed increased P-gp protein levels associated with ubiquitin after A β 40 exposure. We detected no signal in the IgG controls (capillary lysate sample plus IgG antibody) and negative controls (capillary lysate sample but no primary antibody;

Fig. 5A), indicating that the observed signals are specific for P-gp and ubiquitin. Consistent with increased P-gp ubiquitination, PYR-41, a cell-permeable inhibitor of ubiquitin ligase E1, abolished the A β 40-mediated reduction of P-gp protein expression and transport activity levels (Fig. 5C), as well as ubiquitination of P-gp (Fig. 5D). Using the Simple Western assay system (Protein-Simple), we determined the amount of P-gp that was immunoprecipitated by ubiquitin: control samples contained 4.3 ng P-gp protein, samples from capillaries exposed to A β 40 contained 6.9 ng P-gp protein, and samples treated with both A β 40 and PYR-41 contained 3.3 ng P-gp protein based on a P-gp protein standard curve. Data from six independent immunoprecipitation experiments indicate that A β 40 increased the amount of ubiquitinated P-gp by $53 \pm 9.3\%$. Together, these data demonstrate that




Figure 6. Microtubule inhibitors prevent A β 40-mediated P-gp reduction. The microtubule inhibitors brefeldin A (1 μ g/ml) (**A**) and nocodazole (100 nM) (**B**) prevent A β 40-mediated reduction of P-gp protein expression (Western blot) and transport activity (luminal NBD-CSA fluorescence). β -Actin was used as protein loading control for Western blots. Data are mean \pm SEM ($n = 10$ capillaries per treatment group from one brain capillary isolation; pooled tissue from 10 rats). Units are arbitrary fluorescence units (scale, 0–255). *** $p < 0.001$, significantly lower than control.

A β 40 exposure increases P-gp ubiquitination in isolated brain capillaries.

Next, we investigated whether A β 40 triggers internalization of P-gp, which is the step following ubiquitination in the proteasome pathway. We exposed isolated rat brain capillaries to A β 40 for 6 h with or without the microtubule inhibitors, brefeldin A and nocodazole, to stop intracellular trafficking. Figure 6 shows that both inhibitors blocked A β 40-mediated reduction of P-gp protein expression and transport activity levels. These data suggest that blocking intracellular trafficking prevents P-gp internalization from the plasma membrane into the cell.

To verify that the final step of the ubiquitin–proteasome pathway was involved in P-gp reduction, we determined whether P-gp was subject to proteasomal or lysosomal degradation. We exposed isolated rat brain capillaries to A β 40 with or without the proteasome inhibitors lactacystin, MG-132, and bortezomib, or the lysosomal vacuolar type H⁺-ATPase inhibitor bafilomycin A1. All three proteasome inhibitors prevented A β 40-mediated reduction of P-gp protein expression and transport activity levels (Fig. 7A–C), whereas the lysosomal inhibitor bafilomycin A1 had no such effect (Fig. 7D). Consistent with this, we found increased 20S proteasomal activity in isolated rat brain capillaries that were exposed to A β 40 for 6 h (Fig. 7E). The inhibitors themselves had no effect on P-gp protein expression and transport function (Fig. 7F). This suggests that, following ubiquitination and internalization, P-gp is directed to the proteasome for degradation.

Together, the present data demonstrate that exposing brain capillaries to A β 40 triggers ubiquitination, internalization, and proteasomal degradation of P-gp at the blood–brain barrier (Fig. 8).

Discussion

We and others previously showed that P-gp protein expression and transport activity are reduced in human A β -overexpressing AD mouse models (Hartz et al., 2010; Mehta et al., 2013). These data are supported by studies with postmortem human brain tissue that demonstrate P-gp expression and activity levels are lower in the neurovasculature from patients with mild cognitive impairment and AD compared with those in age-matched, healthy individuals (Wijesuriya et al., 2010; Jeynes and Provias, 2011; van Assema et al., 2012; Deo et al., 2014). These studies suggest a link between high A β levels and reduced brain capillary P-gp in AD. However, the cellular mechanism that drives P-gp reduction in the blood–brain barrier in AD has not been unraveled.

In the present study, we demonstrate that nanomolar concentrations of A β 40 decrease P-gp expression and transport activity in rat brain capillaries and we begin to describe the mechanism through which this occurs. Our data show that exposing brain capillaries to monomeric A β 40 decreases P-gp protein expression and transport activity levels in a time- and concentration-dependent manner (Figs. 1–3). At 100 nM, neither aggregated A β 40, nor A β 40_{reverse}, nor A β 42 had any effect (Fig. 4). A β 40 concentrations measured in postmortem brain tissue from AD patients are in the mid to high nanomolar range, similar to the A β 40 concentrations used in the present study (Gravina et al., 1995; Hardy and Selkoe, 2002). Immunoprecipitation demonstrated that A β 40 triggers P-gp ubiquitination, and experiments with microtubule and proteasomal inhibitors indicate that P-gp is internalized and degraded by the proteasome (Figs. 6, 7). Con-




Figure 7. Inhibition of the proteasome prevents A β 40-mediated P-gp reduction. The proteasome inhibitors lactacystin (10 μ M) (**A**), MG-132 (150 nM) (**B**), and bortezomib (100 nM) (**C**) abolish A β 40-mediated reduction of P-gp expression (Western blot) and transport activity (luminal NBD-CSA fluorescence). **D**, The lysosomal inhibitor bafilomycin A1 (10 nM) did not prevent P-gp reduction triggered by A β 40. **E**, The 20S proteasome activity was increased in isolated rat brain capillaries exposed to A β 40 for 6 h. β -Actin was used as protein loading control for Western blots. **F**, The inhibitors PYR-41, nocodazole, and bortezomib had no effect on P-gp protein expression and transport activity. Data are mean \pm SEM ($n = 10$ capillaries per treatment group from one brain capillary isolation; pooled tissue from 10 rats). Units are arbitrary fluorescence units (scale, 0–255). *** $p < 0.001$, significantly lower or higher than control.

sistent with this, 20S proteasomal activity in capillaries was increased by A β 40. Based on these data, we propose that A β 40 activates the ubiquitin–proteasome system at the blood–brain barrier, resulting in P-gp degradation and, thus, reduction in P-gp protein expression and activity levels (Fig. 8). These data for intact brain capillaries demonstrate a cause-and-effect relationship between exposure to nanomolar concentrations of A β 40 and reduced P-gp expression and transport activity.

Recent reports suggest that A β 42 could also be involved in the reduction of blood–brain barrier P-gp. Brenn et al. (2011) implanted an osmotic pump subcutaneously into FVB mice for 24 h

peripheral administration of A β 40 and A β 42, and showed that A β 42, but not A β 40, slightly reduced P-gp mRNA levels in the brain, whereas P-gp protein expression levels remained unchanged. Carrano et al. (2014) exposed a human cerebral microvascular endothelial cell line (hCMEC/D3) to various A β forms for 24 h and found that oligomeric A β 42, but not fibrillary A β 42 or A β 40, reduced P-gp mRNA levels. Park et al. (2014) showed that A β 42-mediated reduction in P-gp protein expression in bEnd.3 cells depended on RAGE and that a yet to-be-identified astrocyte-derived factor attenuated the A β -induced decrease in P-gp expression in a bEnd.3-astrocyte coculture. However, the




Figure 8. Proposed signaling pathway. Based on the data presented here, we propose the following signaling pathway: A β 40 triggers: (1) ubiquitination, (2) internalization, and (3) proteasomal degradation of blood–brain barrier P-gp, which results in reduced P-gp protein expression and transport function.

effects observed in these studies may not be a realistic reflection of the situation in the AD brain because they may be artifacts of administering A β 42 into the periphery (Brenn et al., 2011), of using immortalized cultured cells (Carrano et al., 2014), and of applying excessive A β 42 concentrations (Park et al., 2014). In addition, it is possible that the A β 42 effect on blood–brain barrier P-gp is time-, concentration-, and context-dependent, which could explain some of the discrepancies between our data and those by other groups described above.

Ubiquitination followed by lysosomal or proteasomal degradation plays a crucial role in regulating expression and function of membrane proteins (Ciechanover, 1994; Ciechanover and Iwai, 2004). P-gp is a 180 kDa membrane protein that undergoes endocytosis and recycling, and its half-life has been determined in multidrug-resistant cancer cell lines to be ~14–17 h (Muller et al., 1995; Kim et al., 1997). P-gp trafficking, localization, stability, and function are, in part, regulated by the ubiquitin–proteasome pathway (Loo and Clarke, 1999). One protease-cleavage site of P-gp is in the first extracellular loop near the glycosylation site (Arg113); two more sites (Arg680 and Leu682) are located in the linker region joining the two halves of P-gp (Loo and Clarke, 1998; Nuti and Rao, 2002). Zhang et al. (2004) were the first to show that P-gp stability is regulated by the ubiquitin–proteasome pathway. These authors found that inhibition of N-glycosylation enhances P-gp ubiquitination and degradation, thereby reducing transporter activity (Zhang et al., 2004). In a recent study, Katayama et al. (2013) showed that the ubiquitin E3 ligase subunit FBXO15 and the ubiquitin-conjugating enzyme E2 R1 regulate P-gp expression in human colorectal cancer cell lines. The authors demonstrated that FBXO15 knockdown increases cell-surface P-gp expression and enhances P-gp-mediated efflux, suggesting that the ubiquitin–proteasome system regulates P-gp expression and activity levels. Our study indicates that A β 40 triggers P-gp ubiquitination, internalization, and proteasome-dependent degradation leading to reduction of P-gp expression and activity levels in brain capillaries (Figs. 5–7). We show that the lysosomal inhibitor bafilomycin A does not attenuate A β 40-mediated P-gp reduction, suggesting that proteasomal degradation, rather than lysosomal degradation, reduces P-gp levels (Fig. 7). Recently, we demonstrated that P-gp is a substrate for the ubiquitin ligase NEDD4-1, which is increased in brain capillaries from 9-month-old hAPP mice (Tg2576 model) and may be in-

involved in A β -mediated P-gp reduction (Akkaya et al., 2015). A recent study by Aida et al. (2014) on the ABC transporters BSEP and MRP2 suggests that transporter degradation is multifaceted and complex. The authors propose that, in addition to the ubiquitin–proteasome and lysosomal pathways, proteins destined for degradation can also be routed to a ubiquitination-independent, and bafilomycin-insensitive pathway. Although our data are conclusive, several mechanistic details remain to be determined. For example, it is unknown whether P-gp is mono- or poly-ubiquitinated, which ubiquitin ligases catalyze this step, and which signals drive A β 40 activation of the ubiquitin–proteasome pathway.

The ubiquitin–proteasome system is critical for normal brain function because it regulates proper protein turnover, development, and differentiation, signals transduction, and is responsible for the disposal of unneeded waste proteins (Yi and Ehlers, 2007). In AD, however, the ubiquitin–proteasome system is dysfunctional and is suspected to contribute to the pathogenesis of the disease (Oddo, 2008; Hong et al., 2014). In this regard, the ubiquitin protein ligases, UBE2 and UBE3, are upregulated in AD, and elevated levels of ubiquitinated proteins have been detected in neurofibrillary tangles and A β plaques in postmortem AD brains (Mori et al., 1987; Perry et al., 1987; Keck et al., 2003). Overall, the majority of available studies suggest that the ubiquitin–proteasome system is impaired and defective in neurons in the late-stage AD brain from deceased patients. In contrast, little is known about changes in the subset of the ubiquitin–proteasome system at the blood–brain barrier. In this regard, Deane et al. (2004) showed A β -mediated proteasomal degradation of LRP in brain capillaries from 6- to 9-month-old, transgenic hAPP mice that were cognitively impaired. In isolated brain capillaries from nontransgenic wild-type mice, we found that A β 40 increases proteasome activity and ubiquitylated P-gp levels, resulting in reduced P-gp expression and activity levels (Figs. 5–7). Thus, our data support a possible role for the ubiquitin–proteasome system in reducing P-gp in AD at the level of the blood–brain barrier.

The present experiments show that the time courses of A β 40-induced loss of P-gp transport activity and protein expression do not coincide. Transport activity decreased rapidly with A β 40 exposure, whereas the reduction in transporter expression was delayed (at least past 45 min of exposure). Removal of A β 40 early in the time course fully restored transport activity and did not alter transporter expression in the long term. In 6 h experiments, pharmacologically inhibiting P-gp ubiquitination, trafficking, or degradation at the proteasome abolished the loss of transporter activity and transporter protein expression. One would expect this result when ubiquitination was inhibited, but the lack of effect of A β 40 exposure when trafficking and proteasomal degradation were inhibited suggests a more complex scenario than that depicted in Figure 8. One possibility for P-gp is that both ubiquitination and trafficking are reversible when degradation does not occur over a period of hours. These aspects of the mechanism require further study, as does the mechanism by which A β 40 signals P-gp ubiquitination, internalization, and proteasome activation.

Collectively, our findings and those from other groups indicate that P-gp in the blood–brain barrier is part of the A β brain clearance system and that P-gp protein expression and transport activity levels are reduced in AD (Lam et al., 2001; Cirrito et al., 2005; Kuhnke et al., 2007; Hartz et al., 2010; Mehta et al., 2013). We also demonstrate in rat brain capillaries that A β 40 triggers reduction in P-gp expression and activity levels through the ubiquitin–proteasome system, which, for the first time, provides a plausible mechanism how P-gp is reduced in AD. This implies a pernicious positive feedback loop where reduced P-gp levels lead to increased A β brain accumulation, which in turn drives further P-gp degradation, leading to even greater increases in A β brain levels and eventually AD pathology. Clearly, this scenario could contribute to the progressive nature of AD. In this regard, our data imply that the ubiquitin–proteasome system may potentially serve as an early therapeutic target to protect P-gp from degradation and limit A β from accumulation in the brain, thereby delaying the onset and slowing the progression of AD. Current studies are underway to test the effect of PYR-41, nocodazole, and bortezomib in an AD mouse model *in vivo*.

References

- Aida K, Hayashi H, Inamura K, Mizuno T, Sugiyama Y (2014) Differential roles of ubiquitination in the degradation mechanism of cell surface-resident bile salt export pump and multidrug resistance-associated protein 2. *Mol Pharmacol* 85:482–491. [CrossRef Medline](#)
- Akkaya BG, Zolneric JK, Ritchie TK, Bauer B, Hartz AMS, Sullivan JA, Linton KJ (2015) The multidrug resistance pump ABCB1 is a substrate for the ubiquitin ligase Nedd4–1. *Mol Membr Biol* 32:39–45. [CrossRef Medline](#)
- Bauer B, Yang X, Hartz AM, Olson ER, Zhao R, Kalvass JC, Pollack GM, Miller DS (2006) *In vivo* activation of human pregnane X receptor tightens the blood–brain barrier to methadone through P-glycoprotein up-regulation. *Mol Pharmacol* 70:1212–1219. [CrossRef Medline](#)
- Beccano-Kelly DA, Kuhlmann N, Tatarnikov I, Volta M, Munsie LN, Chou P, Cao LP, Han H, Tapia L, Farrer MJ, Milnerwood AJ (2014) Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice. *Front Cell Neurosci* 8:301. [CrossRef Medline](#)
- Brenn A, Grube M, Peters M, Fischer A, Jedlitschky G, Kroemer HK, Warzok RW, Vogelgesang S (2011) Beta-amyloid downregulates MDR1-P-glycoprotein (Abcb1) expression at the blood–brain barrier in mice. *Int J Alzheimers Dis* 2011:690121. [CrossRef Medline](#)
- Carrano A, Snkhchyan H, Kooij G, van der Pol S, van Horssen J, Veerhuis R, Hoozemans J, Rozemuller A, de Vries HE (2014) ATP-binding cassette transporters P-glycoprotein and breast cancer related protein are reduced in capillary cerebral amyloid angiopathy. *Neurobiol Aging* 35:565–575. [CrossRef Medline](#)
- Ciechanover A (1994) The ubiquitin–proteasome proteolytic pathway. *Cell* 79:13–21. [CrossRef Medline](#)
- Ciechanover A, Iwai K (2004) The ubiquitin system: from basic mechanisms to the patient bed. *IUBMB Life* 56:193–201. [CrossRef Medline](#)
- Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, Paul SM, Zlokovic BV, Piwnicka-Worms D, Holtzman DM (2005) P-glycoprotein deficiency at the blood–brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. *J Clin Invest* 115:3285–3290. [CrossRef Medline](#)
- Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. *Neuron* 43:333–344. [CrossRef Medline](#)
- Deo AK, Borson S, Link JM, Domino K, Eary JF, Ke B, Richards TL, Mankoff DA, Minoshima S, O’Sullivan F, Eyal S, Hsiao P, Maravilla K, Unadkat JD (2014) Activity of P-glycoprotein, a beta-amyloid transporter at the blood–brain barrier, is compromised in patients with mild Alzheimer disease. *J Nucl Med* 55:1106–1111. [CrossRef Medline](#)
- Gravina SA, Ho L, Eckman CB, Long KE, Otvos L Jr, Younkin LH, Suzuki N, Younkin SG (1995) Amyloid beta protein (A beta) in Alzheimer’s disease brain: biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). *J Biol Chem* 270:7013–7016. [CrossRef Medline](#)
- Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. *Science* 297:353–356. [CrossRef Medline](#)
- Hartz AM, Bauer B, Fricker G, Miller DS (2004) Rapid regulation of P-glycoprotein at the blood–brain barrier by endothelin-1. *Mol Pharmacol* 66:387–394. [CrossRef Medline](#)
- Hartz AM, Bauer B, Block ML, Hong JS, Miller DS (2008) Diesel exhaust particles induce oxidative stress, proinflammatory signaling, and P-glycoprotein up-regulation at the blood–brain barrier. *FASEB J* 22:2723–2733. [CrossRef Medline](#)
- Hartz AM, Miller DS, Bauer B (2010) Restoring blood–brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer’s disease. *Mol Pharmacol* 77:715–723. [CrossRef Medline](#)
- Hong L, Huang HC, Jiang ZF (2014) Relationship between amyloid-beta and the ubiquitin–proteasome system in Alzheimer’s disease. *Neuro Res* 36:276–282. [CrossRef Medline](#)
- Jeynes B, Provias J (2011) An investigation into the role of P-glycoprotein in Alzheimer’s disease lesion pathogenesis. *Neurosci Lett* 487:389–393. [CrossRef Medline](#)
- Katayama K, Noguchi K, Sugimoto Y (2013) FBXO15 regulates P-glycoprotein/ABCB1 expression through the ubiquitin–proteasome pathway in cancer cells. *Cancer Sci* 104:694–702. [CrossRef Medline](#)
- Keck S, Nitsch R, Grune T, Ullrich O (2003) Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer’s disease. *J Neurochem* 85:115–122. [CrossRef Medline](#)
- Kim H, Barroso M, Samanta R, Greenberger L, Sztul E (1997) Experimentally induced changes in the endocytic traffic of P-glycoprotein alter drug resistance of cancer cells. *J Physiol* 273:C687–C702. [Medline](#)
- Kuhnke D, Jedlitschky G, Grube M, Krohn M, Jucker M, Mosyagin I, Cascorbi I, Walker LC, Kroemer HK, Warzok RW, Vogelgesang S (2007) MDR1-P-glycoprotein (ABCB1) mediates transport of Alzheimer’s amyloid-beta peptides: implications for the mechanisms of Abeta clearance at the blood–brain barrier. *Brain Pathol* 17:347–353. [CrossRef Medline](#)
- Lam FC, Liu R, Lu P, Shapiro AB, Renoir JM, Sharom FJ, Reiner PB (2001) beta-Amyloid efflux mediated by p-glycoprotein. *J Neurochem* 76:1121–1128. [CrossRef Medline](#)
- LeVine H 3rd (2004) Alzheimer’s beta-peptide oligomer formation at physiologic concentrations. *Anal Biochem* 335:81–90. [CrossRef Medline](#)
- Loo TW, Clarke DM (1998) Quality control by proteases in the endoplasmic reticulum: removal of a protease-sensitive site enhances expression of human P-glycoprotein. *J Biol Chem* 273:32373–32376. [CrossRef Medline](#)
- Loo TW, Clarke DM (1999) The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface. *J Biol Chem* 274:24759–24765. [CrossRef Medline](#)
- Mehta DC, Short JL, Nicolazzo JA (2013) Altered brain uptake of therapeutics in a triple transgenic mouse model of Alzheimer’s disease. *Pharm Res* 30:2868–2879. [CrossRef Medline](#)
- Mori H, Kondo J, Ihara Y (1987) Ubiquitin is a component of paired helical filaments in Alzheimer’s disease. *Science* 235:1641–1644. [CrossRef Medline](#)
- Muller C, Laurent G, Ling V (1995) P-glycoprotein stability is affected by serum deprivation and high cell density in multidrug-resistant cells. *J Cell Physiol* 163:538–544. [CrossRef Medline](#)
- Nuti SL, Rao US (2002) Proteolytic cleavage of the linker region of the human P-glycoprotein modulates its ATPase function. *J Biol Chem* 277:29417–29423. [CrossRef Medline](#)
- Oddo S (2008) The ubiquitin–proteasome system in Alzheimer’s disease. *J Cell Mol Med* 12:363–373. [CrossRef Medline](#)
- O’Neill RA, Bhamidipati A, Bi X, Deb-Basu D, Cahill L, Ferrante J, Gentalen E, Glazer M, Gossett J, Hacker K, Kirby C, Knittle J, Loder R, Mastroieni C, Maclaren M, Mills T, Nguyen U, Parker N, Rice A, Roach D, et al. (2006) Isoelectric focusing technology quantifies protein signaling in 25 cells. *Proc Natl Acad Sci U S A* 103:16153–16158. [CrossRef Medline](#)
- Park R, Kook SY, Park JC, Mook-Jung I (2014) Abeta1–42 reduces P-glycoprotein in the blood–brain barrier through RAGE-NF-kappaB signaling. *Cell Death Dis* 5:e1299. [CrossRef Medline](#)
- Perry G, Friedman R, Shaw G, Chau V (1987) Ubiquitin is detected in neu-

- rofibrillary tangles and senile plaque neurites of Alzheimer disease brains. *Proc Natl Acad Sci U S A* 84:3033–3036. CrossRef Medline
- Schramm U, Fricker G, Wenger R, Miller DS (1995) P-glycoprotein-mediated secretion of a fluorescent cyclosporin analogue by teleost renal proximal tubules. *J Physiol* 268:F46–F52. Medline
- Stine WB, Jungbauer L, Yu C, LaDu MJ (2011) Preparing synthetic A β in different aggregation states. *Methods Mol Biol* 670:13–32. CrossRef Medline
- van Assema DM, Lubberink M, Bauer M, van der Flier WM, Schuit RC, Windhorst AD, Comans EF, Hoetjes NJ, Tolboom N, Langer O, Müller M, Scheltens P, Lammertsma AA, van Berckel BN (2012) Blood–brain barrier P-glycoprotein function in Alzheimer’s disease. *Brain* 135:181–189. CrossRef Medline
- Vogelgesang S, Cascorbi I, Schroeder E, Pahnke J, Kroemer HK, Siegmund W, Kunert-Keil C, Walker LC, Warzok RW (2002) Deposition of Alzheimer’s beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. *Pharmacogenetics* 12:535–541. CrossRef Medline
- Vogelgesang S, Warzok RW, Cascorbi I, Kunert-Keil C, Schroeder E, Kroemer HK, Siegmund W, Walker LC, Pahnke J (2004) The role of P-glycoprotein in cerebral amyloid angiopathy: implications for the early pathogenesis of Alzheimer’s disease. *Curr Alzheimer Res* 1:121–125. CrossRef Medline
- Wijesuriya HC, Bullock JY, Faull RL, Hladky SB, Barrand MA (2010) ABC efflux transporters in brain vasculature of Alzheimer’s subjects. *Brain Res* 1358:228–238. CrossRef Medline
- Yi JJ, Ehlers MD (2007) Emerging roles for ubiquitin and protein degradation in neuronal function. *Pharmacol Rev* 59:14–39. CrossRef Medline
- Zhang Z, Wu JY, Hait WN, Yang JM (2004) Regulation of the stability of P-glycoprotein by ubiquitination. *Mol Pharmacol* 66:395–403. CrossRef Medline
- Zlokovic BV (2005) Neurovascular mechanisms of Alzheimer’s neurodegeneration. *Trends Neurosci* 28:202–208. CrossRef Medline
- Zlokovic BV, Frangione B (2003) Transport–clearance hypothesis for Alzheimer’s disease and potential therapeutic implications in A β metabolism in Alzheimer’s disease. Austin, TX: Landes Bioscience.